Trial Profile

A Multicentre Open-label Phase II Study of Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Ixazomib (Primary) ; Methylprednisolone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms IDARA

Most Recent Events

31 Jan 2024 Last checked against European Clinical Trials Database record.
26 Jan 2024 This trail has been discontinued in France (End Date: 19 Dec 2023), according to European Clinical Trials Database record.
15 Jun 2023 Updated results evaluating efficacy and tolerability of Ixazomib and Daratumumab without Dexamethasone in elderly frail patients with relapsed myeloma , presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com